Integrum AB Series B
The answer first
Does Integrum beat the market?
No, Integrum has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 37% of Nordic stocks
- Quality38
- Value35
- Trend63
No. 87 of 195 in healthcare
Max for seven days
Follow Integrum with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Integrum
Your first answer is free, no account needed.
Do you own Integrum, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Integrum and a few more. Free, no card.
Super Stock+45.9%In short
- Integrum has risen 0.5% over the past year, including dividends.
- Overall, Integrum ranks better than 37% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 88.6%. The price is 91.8% below its peak now.
What do analysts think of Integrum?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 37% of Nordic stocks.
No. 87 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 149 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.04
- Asset turnoverSales divided by everything the company owns0.49
- Return on equityProfit divided by equity−20.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 65 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity1.2
- P/SPrice divided by sales2.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−1.5%
- 6 months+6.2%
- 9 months+4.9%
- 12 months+0.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Integrum
One fund we follow owns Integrum. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Integrum
Integrum AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 33 employees.
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide.


See the full analysis of Integrum.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card